Boston

Share Your News

Biogen (BIIB) Report 24 -Month Interim Analysis from PRIME

11/7/17

By Seeking Alpha

The following slide deck was published by Biogen Inc. in conjunction with this event.

120

PRIME, a Randomized, Double-Blind, Placebo-Controlled Phase 1b Study in Patients With Prodromal or Mild Alzheimer’s Disease 1 1 1 1 Philipp von Rosenstiel MD , Sarah Gheuens, MD, PhD , Tianle Chen, PhD , John O’Gorman, PhD , Ping Chiao, PhD , Guanfang Wang, PhD , Christian von Hehn, MD, PhD , LeAnne Skordos PharmD , Christoph Hock, MD , 3 Roger M Nitsch, MD , Samantha Budd Haeberlein, PhD , Alfred Sandrock, MD, PhD 1 1 2 3 Biogen, Cambridge, MA, USA; Cytel, Cambridge, MA, USA; Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

READ FULL ARTICLE HERE

Posted in Health/Biotech

Stories you Need to Know

David Nevins Interviews Dr. Matthew Frieman, Associate Professor, University of Maryland School of Medicine
Byrna Technologies Reports Record Fourth Quarter And Full Fiscal 2020 Results
Thermo Fisher Scientific Acquires Mesa Biotech
Relivant to Acquire Silicon Therapeutics for $450 Million
Mersana Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Biocytogen Acquires Antibody Discovery Platform
Akebia Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Business Updates
Medisafe Secures $30M in Series C
Moderna Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Updates
Concert Pharmaceuticals Reports 2020 Financial Results and Provides Update on Clinical Programs

Contact Our CEO, Edwin Warfield

For partnerships, content marketing or advertising inquiries, please contact Edwin through his LinkedIn Profile

Connect

© Copyright 2026 citybuzz